© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
This piece explores the history; physical, economic, and psychosocial burden; and clinical pathophysiology of type 1 diabetes to evaluate opportunities for earlier intervention to change the standard of care for this disease and improve overall outcomes.
June 14th 2021, 9:30pm
National Institutes of Health–sponsored research examines the underlying cause of COVID-19–induced diabetes.
June 9th 2021, 4:35pm
Results of a systematic review underscore implications of increased rates of metabolic syndrome among youth with type 1 diabetes.
June 7th 2021, 6:00pm
Results of a nationwide study show earlier onset of type 1 diabetes (T1D) is associated with worse glycemic outcomes and presence of albuminuria.
June 4th 2021, 3:00pm
Results of a study conducted in California suggest some adolescents with type 1 diabetes (T1D) improved their glycemic control during the COVID-19 lockdown.
June 2nd 2021, 5:00pm
Data from a longitudinal study reveal poor glycemic control and blood pressure management may contribute to cognitive decline in older patients with type 1 diabetes.
May 28th 2021, 6:39pm
FDA panel members acknowledged the challenges and significant unmet need that patients with T1D face, along with the small size of the pivotal study.
May 25th 2021, 1:00pm
A recent analysis of The Environmental Determinants of Diabetes in the Young study found maternal diet has no impact on type 1 diabetes and islet autoimmunity (IA) risk.
May 19th 2021, 1:30pm
Results of a qualitative study outline widely held cost considerations regarding diabetes technology in the type 1 diabetes (T1D) community.
May 17th 2021, 2:00pm
Frank Martin, PhD, director of research at JDRF, discusses the organization's efforts to educate regulators about the disease.
May 10th 2021, 4:36pm
The FDA cleared Bigfoot BioMedical's Diabetes Management System.